Home » Ozempic Approved for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes
Ozempic Approved for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes
Novo Nordisk’s Ozempic (semaglutide) received FDA approval for injection 0.5 mg or 1 mg to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
The approval was based on the results of a two-year clinical trial in which Ozempic significantly reduced the risk of the occurrence of a three-component MACE endpoint consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke.
The drug was originally approved in 2017 for glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May